Atlas Trials

Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT

Clinical trial NCT07309211 · RECRUITING

Trial details

NCT number
NCT07309211
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
RECRUITING
Study type
OBSERVATIONAL
SCLC, Limited Stage
Start date
2025-07-08
Primary completion
2025-12-01
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.